Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Definium Therapeutics will host a webcast on June 22, 2026, at 8:00 a.m. EDT to discuss topline results from its Phase 3 Emerge study. The Emerge study evaluates a single 100 µg dose of DT120 ODT in 149 adults with major depressive disorder, using change in MADRS total score at Week 6 as the primary endpoint.
Key figures
- Drug Name
- DT120 ODT
- Phase Of Trial
- Phase 3
- Dose
- 100 µg
- Study name
- Emerge
- Primary endpoint
- change from baseline in MADRS total score at Week 6
- Participant count
- 149
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.